Chronic Obstructive Pulmonary Disease Biomarkers

Despite significant decreases in morbidity and mortality of cardiovascular diseases (CVD) and cancers, morbidity and cost associated with chronic obstructive pulmonary disease (COPD) continue to be increasing. Failure to improve disease outcomes has been related to the paucity of interventions improving survival. Insidious onset and slow progression halter research successes in developing disease-modifying therapies. In part, the difficulty in finding new therapies is because of the extreme heterogeneity within recognized COPD phenotypes. Novel biomarkers are necessary to help understand the natural history and pathogenesis of the different COPD subtypes. A more accurate phenotyping and the ability to assess the therapeutic response to new interventions and pharmaceutical agents may improve the statistical power of longitudinal clinical studies. In this study, we will review known candidate biomarkers for COPD, proposed pathways of pathogenesis, and future directions in the field.

Kaynakça

Stockley RA. Biomarkers in COPD: time for a deep breath. Thorax 2007; 62: 657-60. [CrossRef]

Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107 (5 Suppl): 187S-93S. [CrossRef]

Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-65. [CrossRef]

Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95. [CrossRef]

Jones PW, Agusti AG. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 2006; 27: 822-32. [CrossRef]

Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: expla- nation and elaboration. Ann Intern Med 2003; 138: W1-12. [CrossRef]

Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122.

Gelb AF, Yamamoto A, Verbeken EK, Nadel JA. Unraveling the Pathophy- siology of the Asthma COPD Overlap Syndrome: Unsuspected mild cent- rilobular emphysema is responsible for loss of lung elastic recoil in never smoked asthmatics with persistent expiratory airflow limitation. Chest 2015; 148: 313-20. [CrossRef]

Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Res- pir Crit Care Med 2010; 182: 598-604. [CrossRef]

Agusti A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outco- mes in COPD: a novel phenotype. PloS One 2012; 7: e37483. [CrossRef]

Sin DD, Man SF. Why are patients with chronic obstructive pulmonary di- sease at increased risk of cardiovascular diseases? The potential role of sys- temic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-9. [CrossRef]

Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-54. [CrossRef]

Sin DD, Man SF, Marciniuk DD, Ford G, FitzGerald M, Wong E, et al. The ef- fects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-14. [CrossRef]

Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capa- city index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12. [CrossRef]

de Torres JP, Casanova C, Marin JM, Pinto-Plata V, Divo M, Zulueta JJ, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax 2014; 69: 799-804. [CrossRef]

Divo M, Cote C, de Torres JP, Casanova C, Marin JM, Pinto-Plata V, et al. Co- morbidities and risk of mortality in patients with chronic obstructive pul- monary disease. Am J Respir Crit Care Med 2012; 186: 155-61. [CrossRef]

Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, et al. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174: 6-14. [CrossRef]

Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflam- matory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185: 1065- 72. [CrossRef]

Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvas- cular mortality: an individual participant meta-analysis. JAMA 2005; 294: 1799-809.

Valvi D, Mannino DM, Mullerova H, Tal-Singer R. Fibrinogen, chronic obst- ructive pulmonary disease (COPD) and outcomes in two United States co- horts. Int J Chron Obstruct Pulmon Dis 2012; 7: 173-82.

Gumus A, Haziroglu M, Gunes Y. Association of serum magnesium levels with frequency of acute exacerbations in chronic obstructive pulmonary disease: a prospective study. Pulm Med 2014; 2014: 329476. [CrossRef]

Polatli M, Cakir A, Cildag O, Bolaman AZ, Yenisey C, Yenicerioglu Y. Microal- buminuria, von Willebrand factor and fibrinogen levels as markers of the severity in COPD exacerbation. J Thromb Thrombolysis 2008; 26: 97-102. [CrossRef]

Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, et al. Serum bilirubin and risk of respiratory disease and death. JAMA 2011; 305: 691-7. [CrossRef]

Ryter SW, Morse D, Choi AM. Carbon monoxide and bilirubin: potential therapies for pulmonary/vascular injury and disease. Am J Respir Cell Mol Biol 2007; 36: 175-82. [CrossRef]

Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003; 2: 717-26. [CrossRef]

Li M, Guo L, Wang H, Wang T, Shen Y, Liao Z, et al. RAGE-ligands axis: A new 'driving force' for cigarette smoke-induced airway inflammation in COPD? Respirology 2015; 20: 998-9. [CrossRef]

Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014; 69: 666-72. [CrossRef]

Chapman KR, Burdon JG, Piitulainen E, Sandhaus RA, Seersholm N, Stocks JM, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, place- bo-controlled trial. Lancet 2015; 386: 360-8. [CrossRef]

Coxson HO. Quantitative chest tomography in COPD research: chairman's summary. Proc Am Thorac Soc 2008; 5: 874-7. [CrossRef]

Coxson HO, Dirksen A, Edwards LD, Yates JC, Agusti A, Bakke P, et al. The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the EC- LIPSE study. Lancet Respir Med 2013; 1: 129-36. [CrossRef]

Han MK, Kazerooni EA, Lynch DA, Liu LX, Murray S, Curtis JL, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study: as- sociated radiologic phenotypes. Radiology 2011; 261: 274-82. [CrossRef]

White ES, Brown KK, Collard HR, Conoscenti CS, Cosgrove GP, Flaherty KR, et al. Open-access biorepository for idiopathic pulmonary fibrosis. The way forward. Ann Am Thorac Soc 2014; 11: 1171-5. [CrossRef]

Pinto-Plata V, Toso J, Lee K, Park D, Bilello J, Mullerova H, et al. Profiling se- rum biomarkers in patients with COPD: associations with clinical parame- ters. Thorax 2007; 62: 595-601. [CrossRef]

Biomarker Qualification Program. FDA; [updated 04/08/2015]; Available from: http://www.fda.gov/drugs/developmentapprovalprocess/drugde- velopmenttoolsqualificationprogram/ucm284076.htm.

Celli BR, Decramer M, Wedzicha JA, Wilson KC, Agustí A, Criner GJ, et al. An official american thoracic society/european respiratory society statement: research questions in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 191: e4-e27. [CrossRef]

Bafadhel M, McKenna S, Terry S, Mistry V, Pancholi M, Venge P, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186: 48-55. [CrossRef]

Turino GM, Ma S, Lin YY, Cantor JO, Luisetti M. Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 184: 637-41. [CrossRef]

Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 982-8. [CrossRef]

Lomas DA, Lipson DA, Miller BE, Willits L, Keene O, Barnacle H, et al. An oral in- hibitor of p38 MAP kinase reduces plasma fibrinogen in patients with chronic obstructive pulmonary disease. J Clin Pharmacol 2012; 52: 416-24. [CrossRef]

Mannino DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation: data from the Third National Health and Nutrition Examination. Am J Med 2003; 114: 758-62. [CrossRef]

Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010; 375: 132-40. [CrossRef]

Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pul- monary disease. Am J Respir Crit Care Med 2006; 174: 867-74. [CrossRef]

Shorter JH, Nelson DD, McManus JB, Zahniser MS, Sama SR, Milton DK. Clinical study of multiple breath biomarkers of asthma and COPD (NO, CO(2), CO and N(2)O) by infrared laser spectroscopy. J Breath Res 2011; 5: 037108. [CrossRef]

Bozinovski S, Hutchinson A, Thompson M, Macgregor L, Black J, Giannakis E, et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 269- 78. [CrossRef]

Yoon HI, Li Y, Man SF, Tashkin D, Wise RA, Connett JE, et al. The complex relationship of serum adiponectin to COPD outcomes COPD and adipone- ctin. Chest 2012; 142: 893-9. [CrossRef]

Suzuki M, Makita H, Ostling J, Thomsen LH, Konno S, Nagai K, et al. Lower leptin/adiponectin ratio and risk of rapid lung function decline in chro- nic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11: 1511-9. [CrossRef]

Barouchos N, Papazafiropoulou A, Iacovidou N, Vrachnis N, Barouchos N, Armeniakou E, et al. Comparison of tumor markers and inflammatory bio- markers in chronic obstructive pulmonary disease (COPD) exacerbations. Scand J Clin Lab Invest 2015; 75: 126-32. [CrossRef]

Valipour A, Schreder M, Wolzt M, Saliba S, Kapiotis S, Eickhoff P, et al. Cir- culating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pul- monary disease. Clinical Sci (Lond) 2008; 115: 225-32. [CrossRef]

Hill J, Heslop C, Man SF, Frohlich J, Connett JE, Anthonisen NR, et al. Circu- lating surfactant protein-D and the risk of cardiovascular morbidity and mortality. Eur Heart J 2011; 32: 1918-25. [CrossRef]

Vestbo J, Edwards LD, Scanlon PD, Yates JC, Agusti A, Bakke P, et al. Chan- ges in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365: 1184-92. [CrossRef]

Kaynak Göster

Solunum
  • ISSN: 1302-4922
  • Yayın Aralığı: Yılda 0 Sayı
  • Başlangıç: 2018

1.1b439